en · de · es · pt
sr9009-notes.peptides4962.com › Topic › Background And Receptor Mechanism — Practical Notes

Background And Receptor Mechanism — Practical Notes

By Editorial Desk · published 2026-07-14 · last reviewed 2026-07-31 · Topic

nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Related pages on this site

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Further detail

Planar cell polarity depends on an asymmetry created by the transmembrane proteins Van Gogh (Vang), Frizzled (Fz), and Flamingo (Fmi), as well as the cytoplasmic proteins Prickle (Pk), Dishevelled (Dsh), and Diego (Dgo). Although the proteins are initially evenly distributed around the cell, through a combination of mutual attraction and repulsion they end up grouped in two clusters at opposite ends of the cell. The proximal end contains bound Vang–Pk complexes, while the distal end contains Fz–Dsh–Dgo. The Vang and Fz proteins are bound together between neighboring cells with Fmi. Depending on the tissue, other protein complexes, such as the Fat–Dachsous (Ft–Ds) system, may also play a role in forming cell polarity. The mechanism by which the polarity direction is initially determined is unclear. The main proposed mechanisms are the concentration gradients of the Ft–Ds system, the noncanonical Wnt signaling pathway, and mechanical forces acting on the shape of the tissue.

== Publications == Collier was a co-editor of the eighth edition and editor-in-chief of the five-volume ninth edition of the "microbiologist’s bible", Topley and Wilson's Principles of Bacteriology and Immunity (now Topley and Wilson's Microbiology and Microbial Infections), which won the Society of Authors' 1998 award in the advanced edited book category.He was also joint editor of Developments in Antiviral Chemotherapy (1980).He was a co-author of Human Virology (1993).

== Related conditions == Disorders that are clinically similar are konzo and Lytico-bodig disease. Konzo means "tied legs" in the Yaka language, and is common in some African people in central and eastern parts of the continent who are consuming diets poor in protein. The possible molecule causing this problem is thiocyanate, which stimulates AMPA receptors.

Sources: en.wikipedia.org

Supporting material

Immunohistochemical studies have revealed that AADC is expressed in various neuronal cell types such as serotonergic and catecholaminergic neurons. Neurons that express AADC but are not considered classical monoaminergic cell neurons are termed D cells. Cells that are immunoreactive for AADC have also been found in the human brainstem. These cells include melanin-pigmented cells that are typically designated as catecholaminergic and may also be serotonergic. Significant localization of dopaminergic cells that are also immunoreactive for AADC is reported in the substantia nigra, ventral tegmental area, and the mesencephalic reticular formation. Unlike previous reports on animal models, nonaminergic (D cells) are unlikely to be observed in the human brain.

Iraqi commandos infiltrated the Kuwaiti border first to prepare for the major units, which began the attack at midnight. The Iraqi attack had two prongs, with the primary attack force driving south straight for Kuwait City down the main highway, and a supporting attack force entering Kuwait farther west, but then turning and driving east, cutting off Kuwait City from the country's southern half. The commander of a Kuwaiti armored battalion, 35th Armoured Brigade, deployed them against the Iraqi attack and conducted a robust defense at the Battle of the Bridges near Al Jahra, west of Kuwait City. Kuwaiti aircraft scrambled to meet the invading force, but approximately 20% were lost or captured. A few combat sorties were flown against Iraqi ground forces. The main Iraqi thrust into Kuwait City was conducted by commandos deployed by helicopters and boats to attack the city from the sea, while other divisions seized the airports and two airbases. The Iraqis attacked the Dasman Palace, the Royal Residence of Kuwait's emir, Jaber Al-Ahmad Al-Jaber Al-Sabah, which was defended by the Emiri Guard supported with M-84 tanks. In the process, the Iraqis killed Fahad Al-Ahmed Al-Jaber Al-Sabah, the Emir's youngest brother. Within 12 hours, most resistance had ended within Kuwait, and the royal family had fled, allowing Iraq to control most of Kuwait. After two days of intense combat, most of the Kuwaiti military were either overrun by the Iraqi Republican Guard, or had escaped to Saudi Arabia. The emir and key ministers fled south along the highway for refuge in Saudi Arabia.

== Historical significance == Enteropeptidase was discovered by Ivan Pavlov, who was awarded the 1904 Nobel Prize in Physiology or Medicine for his studies of gastrointestinal physiology. It is the first known enzyme to activate other enzymes, and it remains a remarkable example of how serine proteases have been crafted to regulate metabolic pathways. The inert function of digestive enzymes within the pancreas was known, as compared to their potent activity within the intestine, but the basis of this difference was unknown. In 1899, Pavlov's student, N. P. Schepowalnikov, demonstrated that canine duodenal secretions dramatically stimulated the digestive activity of pancreatic enzymes, especially trypsinogen. The active principle was recognized as a special enzyme in the intestine that could activate other enzymes. Pavlov named it enterokinase. The debate of whether enterokinase was a cofactor or enzyme was resolved by Kunitz, who showed that the activation of trypsinogen by enterokinase was catalytic. In the 1950s, cattle trypsinogen was shown to be activated autocatalytically by cleavage of an N-terminal hexapeptide. The more precise IUBMB name enteropeptidase has been in existence since 1970. However, the original name ‘enterokinase’ has a long history and remains in common use.

The tetrahydrofuran ring is found in diverse natural products including lignans, acetogenins, and polyketide natural products. Diverse methodology has been developed for the synthesis of substituted THFs.

Sources: en.wikipedia.org

Supporting material

=== Occurrence of alkanes on Earth === Traces of methane gas (about 0.0002% or 1745 ppb) occur in the Earth's atmosphere, produced primarily by methanogenic microorganisms, such as Archaea in the gut of ruminants. The most important commercial sources for alkanes are natural gas and oil. Natural gas contains primarily methane and ethane, with some propane and butane: oil is a mixture of liquid alkanes and other hydrocarbons. These hydrocarbons were formed when marine animals and plants (zooplankton and phytoplankton) died and sank to the bottom of ancient seas and were covered with sediments in an anoxic environment and converted over many millions of years at high temperatures and high pressure to their current form. Natural gas resulted thereby for example from the following reaction:

In February 2016, a Higher School of Economics university academic and Harvard University visiting scholar Yuval Weber wrote on E-International Relations that "the world is not entering Cold War II", stating that the current tensions and ideologies of Russia and Western countries are not similar to those of the original Cold War, that conflicts in Europe and the Middle East do not destabilise other areas geographically, and that Russia "is far more integrated with the outside world than the Soviet Union ever was". However, he suggested that Russia and the West were in the midst of a "mini-Cold War".

==== Advantages ==== The dog's simple gastrointestinal tract contains a vast array of microbial populations; some members of this very diversified community include Fusobacteriota, Pseudomonadota, and Actinomycetota. The gut microbiota of the dog will be comparable to that of the owners due to similar environmental impacts. Not only are the microbes influenced by the dog's environment, but they are also affected by the macronutrient content of the dog's diet. The populations present and health status of the microbiota found within the gut can alter the physiological and metabolic functions of the dog, which then subsequently affects susceptibility to disease development. Fermentation and digestion in the hindgut of a dog can potentially be improved depending on the source and the concentration of protein provide in a diet. Greater digestibility due to higher quality ingredients, in addition to lower protein concentrations within a diet, will help promote beneficial outcomes in assisting the health of a dog's gastrointestinal tract. Higher protein entering the gut will lead to more putrefaction that give rise to various toxins including carcinogens and increase the chances of many bowel diseases, such as colorectal cancer. The age of dogs and cats is inversely proportional to protein consumption. As they age, the protein requirement decreases due to lower level of pepsin in their stomachs. There has also been discussion about higher protein content in diets being inversely related with lifespan (i.e.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Network